4 stars based on
BioInvent's Annual General Meeting the "AGM" on 17 May resolved to elect Dharminder Chahal and Niklas Prager as new board members, to implement a Board share program for the members of the Board and to implement a long-term incentive program for the company's management and other key persons. The AGM voted in favor of adopting the income statements and balance sheets for the Group and the parent company for the financial yearand decided that no dividend should be declared for the financial year Nilsson was re-elected Chairman of the Option att kopa aktier.
In connection hereby it was resolved that the fees for Board members who elect to not participate in the Board share program resolved by the general meeting shall amount to SEKto the Chairman of the Board and SEKeach to the other members of the Board unchanged.
Fee for committee work shall not be paid to the Chairman of the Board. Further, the AGM resolved in accordance option att kopa aktier the Board's proposal on guidelines for remuneration of executive management.
The AGM option att kopa aktier to approve the Nomination Committee's proposal for a Board share program for the members of the Board, whereby the members of the Board who wish to participate in the program are allocated 45 per cent of the basic fee for the Board assignment option att kopa aktier the form of shares in BioInvent to a number that at the time of allocation in terms of value is equivalent to 45 per cent of the fee.
The resolution includes a directed issue of a maximum ofwarrants corresponding to approximately 0. Subscription of shares by virtue of the warrants shall be made no later than 30 July and the subscription price per option att kopa aktier shall amount to the share's quota value presently SEK 0. Further, the AGM resolved option att kopa aktier approve the Board's proposal regarding the implementation of a long-term incentive program in the form of an option program comprising management and other key persons, entailing a directed issue of maximum of 7, warrants corresponding to approximately 2.
The program means that the participants may be allotted a maximum of 5, warrants depending on performance and the company's long-term value growth. Each option entitles the holder to subscribe for one new share in BioInvent during the period from the day of release of the company's year-end report for the financial year up to option att kopa aktier including 15 December The subscription price per share shall correspond to per cent of the volume-weighted average price paid for the company's share on Nasdaq Stockholm during option att kopa aktier trading days as from and including 18 May Last, the AGM authorised the Board of Directors to resolve on the issue of new shares, on one or several occasions during the period up to the next annual general meeting.
The number of shares to be issued by virtue of the authorisation shall option att kopa aktier exceed 15 per cent of the registered share capital as per the date of the resolution on the issue of new shares.
The issue may take place with or without a deviation from the shareholders' preferential right and with or without provisions on contribution in kind or set-off option att kopa aktier any other terms. The purpose of the authorisation is to increase the company's financial flexibility and enable acquisitions by payment of shares.
At a deviation from the shareholders' preferential right, the issue rate shall be determined option att kopa aktier accordance with market conditions. Other terms may be resolved by the Board. BINV is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells T-regs and tumour-associated myeloid cells.
In Decemberthe Company signed a strategic research collaboration with Pfizer Inc. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials.
For further information, please contact: Magnus Gustavsson Art Director: Fondinformation levereras och uppdateras dagligen av Morningstar Sweden AB. Aktien som ser mest lockande ut.